Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
SYNOPHYLATE is a theophylline sodium glycinate oral elixir, a xanthine bronchodilator used primarily for respiratory conditions such as asthma and COPD. The drug works by relaxing bronchial smooth muscle and stimulating respiratory centers in the medulla. It represents a legacy small-molecule therapeutic from the mid-20th century.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30% index), commercial teams are likely focused on margin defense and operational efficiency rather than growth expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
SYNOPHYLATE currently has zero linked job openings, reflecting its status as a mature legacy product with limited growth trajectory. Career opportunities on this product are primarily in defensive commercial roles focused on market maintenance, margin optimization, and managed decline rather than expansion or innovation initiatives.
Worked on SYNOPHYLATE at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.